Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans.

Publication ,  Journal Article
Schell, WA; De Almeida, GM; Dodge, RK; Okonogi, K; Perfect, JR
Published in: Antimicrob Agents Chemother
October 1998

Multiple isolates of Cryptococcus neoformans, including those with fluconazole resistance, were tested to assess the in vitro activity of the new triazole TAK-187. MICs of TAK-187 were at least eightfold lower than those of fluconazole, and fungicidal concentrations for most isolates were 4 microg/ml or less. TAK-187 also was evaluated as intermittent therapy using two dosages in a rabbit model of experimental cryptococcal meningitis. Compared to daily treatment with fluconazole, as little as two doses of TAK-187 given 7 days apart were found to be effective. Plasma and cerebrospinal fluid TAK-187 concentrations were many times higher than MICs and fungicidal concentrations. Based upon its therapeutic efficacy and long half-life in the rabbit model, TAK-187 should be investigated for intermittent dosing in treatment or suppression of cryptococcal infections in humans.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Antimicrob Agents Chemother

DOI

ISSN

0066-4804

Publication Date

October 1998

Volume

42

Issue

10

Start / End Page

2630 / 2632

Location

United States

Related Subject Headings

  • Triazoles
  • Rabbits
  • Microbiology
  • Microbial Sensitivity Tests
  • Cryptococcus neoformans
  • Cryptococcosis
  • Antifungal Agents
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
  • 3207 Medical microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schell, W. A., De Almeida, G. M., Dodge, R. K., Okonogi, K., & Perfect, J. R. (1998). In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. Antimicrob Agents Chemother, 42(10), 2630–2632. https://doi.org/10.1128/AAC.42.10.2630
Schell, W. A., G. M. De Almeida, R. K. Dodge, K. Okonogi, and J. R. Perfect. “In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans.Antimicrob Agents Chemother 42, no. 10 (October 1998): 2630–32. https://doi.org/10.1128/AAC.42.10.2630.
Schell WA, De Almeida GM, Dodge RK, Okonogi K, Perfect JR. In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1998 Oct;42(10):2630–2.
Schell, W. A., et al. “In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans.Antimicrob Agents Chemother, vol. 42, no. 10, Oct. 1998, pp. 2630–32. Pubmed, doi:10.1128/AAC.42.10.2630.
Schell WA, De Almeida GM, Dodge RK, Okonogi K, Perfect JR. In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1998 Oct;42(10):2630–2632.

Published In

Antimicrob Agents Chemother

DOI

ISSN

0066-4804

Publication Date

October 1998

Volume

42

Issue

10

Start / End Page

2630 / 2632

Location

United States

Related Subject Headings

  • Triazoles
  • Rabbits
  • Microbiology
  • Microbial Sensitivity Tests
  • Cryptococcus neoformans
  • Cryptococcosis
  • Antifungal Agents
  • Animals
  • 3214 Pharmacology and pharmaceutical sciences
  • 3207 Medical microbiology